Replies to post #13202 on Mast Therapeutics, Inc. (MSTX)

[buy4long]

Okaly-So very negative...
How do you propose that a startup biotech with no product on the market secure funds? Debt is just now coming into the picture because of the likelihood of EPIC success. Prior to this, MSTX, like every other high risk/high reward startup biotech, sells stock.

And the Adventrx team that you conveniently tie to the current MSTX management is long gone.

Just adding a bit of balance.

[protagonist12]

Nice to see Sheff taking a cautious approach...